



Resolution n° 3-2016-e

Enabling access to a robust and well-tolerated new-generation first-line antiretroviral treatment in low-income countries

Recalling Resolution n°3-2015-e, in which the UNITAID Board provided its go-ahead for the development by the UNITAID Secretariat of a full draft grant agreement package for the proposed Project '*Enabling access to a robust and well-tolerated new-generation first-line antiretroviral treatment in low-income countries*' submitted by Institut Bouisson Bertrand (IBB) ("the Project"); and

Noting the alignment of this Project with the Board-approved Area for Intervention: 'Improving Adult Antiretroviral Therapy in Low and Middle-income Countries: Providing Support for Evidence-gathering on the Use of New Priority Antiretroviral Regimens for First and Second-line Therapy';

The Board now authorizes, subject to availability of funds, the Executive Director to commit up to **USD 2,450,223** for the Project.

Funding is conditional upon signature of the draft grant agreement between UNITAID and IBB.

Lead Organisation: Institut Bouisson Bertrand (IBB)

Project Duration: 5 years including post-trial access and monitoring.

Philippe Douste-Blazy
Chair of the UNITAID Executive Board

Date: 14/06/2016